Use of COVID-19 Vaccines in the United States

Interim Clinical Considerations

Print
Related Pages
Summary of recent changes (last updated September 15, 2023):
  • Recommendations for use of the 2023–­2024 formulations of Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine:
    • Everyone ages 5 years and older is recommended to receive 1 dose of updated (2023–­2024 Formula) mRNA COVID-19 vaccine
    • Children ages 6 months–4 years
      • Initial vaccination: should receive either 2 doses of updated (2023­–2024 Formula) Moderna or 3 doses of updated (2023–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine
      • Received previous mRNA doses: need 1 or 2 doses of updated (2023–­2024 Formula) Moderna or updated (2023­–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine, depending on the number of prior doses
    • People who are moderately or severely immunocompromised
      • Initial vaccination: should receive a 3-dose series of updated (2023–­2024 Formula) Moderna or updated (2023–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine
      • Received previous mRNA doses: need 1 or 2 doses of updated (2023­–2024 Formula) Moderna or updated (2023–­2024 Formula) Pfizer-BioNTech COVID-19 vaccine, depending on the number of prior doses
      • May receive 1 or more additional updated (2023–­­2024 Formula) mRNA COVID-19 vaccine doses
    • Bivalent mRNA COVID-19 vaccines are no longer recommended in the United States
  • Updated guidance for COVID-19 vaccination and myocarditis or pericarditis
  • Updated guidance for COVID-19 vaccination and Multisystem Inflammatory Syndrome (MIS) in children (MIS-C) and in adults (MIS-A)
  • Reorganization and consolidation of sections on contraindications and precautions, including allergic reactions to COVID-19 vaccines
Get Email Updates

Receive email updates about this page.

What’s this?

Get Email Updates
COVID-19 Vaccines, Recommendations, and Schedules
Implementation
Safety
Special Situations and Populations
Appendices